NF-κB-IN-20

NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI) [1].

Product Specifications

UNSPSC

12352005

Target

Heme Oxygenase (HO) ; Interleukin Related; Keap1-Nrf2; NF-κB; Reactive Oxygen Species (ROS) ; SOD; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Inflammation/Immunology

Smiles

O=C(N(C)/C=C\C1=CC=CC=C1)/C=C/C2=CC(OC)=C(OC)C(OC)=C2

Molecular Formula

C21H23NO4

Molecular Weight

353.41

References & Citations

[1]Song L, et al. Synthesis and evaluation of lansiumamide B analogues to ameliorate acute lung injury by reducing oxidative stress and inflammation via Keap1/Nrf2/NF-κB pathway. Eur J Med Chem. 2025 Dec 5;299:118052.